Interferons Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 10.15 Billion |
| Market Size (2029) | USD 12.30 Billion |
| CAGR (2024 - 2029) | 3.91 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Interferons Market Analysis
The Interferons Market size is estimated at USD 10.15 billion in 2024, and is expected to reach USD 12.30 billion by 2029, growing at a CAGR of 3.91% during the forecast period (2024-2029).
The increasing prevalence of diseases such as hepatitis, multiple sclerosis, and cancers and the high target affinity and specificity of interferons are actively affecting the growth of the market.
Interferons, particularly interferon alpha, have been a cornerstone in the treatment of chronic hepatitis B and C. Although direct-acting antivirals (DAAs) have largely supplanted interferons for hepatitis C, interferons remain an option, especially in certain clinical situations or where DAAs are unavailable. The ongoing need for hepatitis management, particularly in regions with high prevalence rates, supports sustained demand for interferon-based treatments. For instance, according to data published by the World Health Organization in April 2024, around 254 million individuals globally were affected by chronic hepatitis B in 2022, witnessing 1.2 million new infections each year. The disease led to roughly 1.1 million fatalities in 2022, predominantly from cirrhosis and liver cancer. Thus, the high burden of hepatitis B is expected to increase demand for the treatment, with interferons contributing to the market growth.
Further, the high burden of multiple sclerosis (MS) is expected to create an opportunity for interferon beta development, propelling market growth. For instance, according to data published by the Multiple Sclerosis International Federation in 2024, the global prevalence of MS stood at an estimated 2.9 million in 2023, marking an increase from 2.8 million in 2020. As the prevalence of MS continues to rise, there is a continued demand for effective disease-modifying therapies, including interferons, to manage the condition and improve patient outcomes is likely to propel the market growth.
Market players drive growth through strategic initiatives, including product launches, clinical developments, securing approvals, and forming partnerships. For instance, in August 2023, iX Biopharma Ltd unveiled its latest development program, IXB-322. This innovative wafer, containing a low dose of interferon alpha (≤ 1000 IU), is designed for sublingual delivery. Its primary aim is to prevent and treat respiratory viral illnesses, including COVID-19, influenza, and respiratory syncytial virus (“RSV”). This approach is being compared to treatment with PEG-IFNα alone. Thus, such trials lead to innovative launches to create more treatment options for MS market players, which are anticipated to propel market growth.
Therefore, owing to the aforementioned factors, such as the high prevalence of chronic diseases like hepatitis and cancer and product approvals, the market is anticipated to grow during the study period. However, the high research and development costs are likely to impede market growth.
Interferons Market Trends
The Leukemia Segment is Expected to Hold a Significant Market Share During the Forecast Period
Interferon alpha is often used in treating chronic myeloid leukemia (CML). The segment is expected to show stable growth during the forecast period due to the high burden of leukemia and rising product approvals and launches by market players.
According to the American Cancer Society (ACS) 2024 report, 1.0 million new cancer cases were diagnosed in the United States by the first half of 2024. Out of the reported new cancer cases, leukemia was reported with 62,770 new cases, and lymphoma with 89,190 new cases.
Additionally, the Leukemia Foundation's 2023 update reveals that in 2023, 19,400 Australians received a diagnosis of blood cancers, including leukemia, lymphoma, and myeloma. This was equivalent to 53 people daily or one person every 27 minutes. The same source stated that 135,000 individuals were living with blood cancer in Australia in 2023, and more than 275,000 Australians are expected to be living with blood cancer by 2035. Thus, the high burden of leukemia is expected to bolster the segment growth during the forecast period.
Additionally, ongoing research and development activities for interferon therapy in treating leukemia are expected to drive market innovation and growth during the forecast period. For instance, in February 2024, the University of Pittsburgh announced a Phase 2 interferon-γ (IFN-γ) trial in combination with donor leukocyte infusion (DLI). The trial targets relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-allogeneic hematopoietic stem cell transplantation (alloSCT). Based on the positive results of the previous Phase 1 trial, this Phase 2 study intends to strengthen its findings by gathering leukemia cells before and after in vivo IFN-γ therapy. Therefore, these ongoing clinical trials are anticipated to contribute to the growth of this field.
Therefore, owing to the high burden of leukemia, the company's research and development for developing an innovative product are anticipated to propel the segment's growth during the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America is expected to hold a significant share of the interferons market due to the high burden of cancer coupled with developed medical and healthcare establishments and the launch of advanced products in the region.
The high burden of hepatitis in the region is expected to propel the growth of the market. For instance, as per Center for Disease Control and Prevention data updated in April 2024, the United States reported 13,300 new cases of hepatitis B in 2022, highlighting a significant public health concern that requires ongoing monitoring and intervention. Thus, the high burden of hepatitis B is expected to increase demand for the treatment, with interferons contributing to the market growth.
Interferon alpha treats several cancers, including malignant melanoma and renal cell carcinoma. It boosts the immune system's capacity to identify and eliminate cancer cells. With cancer incidence rates increasing globally, the need for effective treatment options, including interferons, drives market demand. For instance, according to the American Cancer Society 2024, 81,610 new kidney and renal pelvis cases were diagnosed in the United States. Most kidney cancers are renal cell carcinomas. Hence, the high burden of renal cell carcinoma is anticipated to propel the market growth during the forecast period.
Moreover, the growth of the market in North America is fueled by the presence of key players, increasing awareness initiatives, and the launch of innovative products in the region. Moreover, in May 2024, CytomX Therapeutics Inc. and Merck (called MSD outside the United States and Canada) entered a collaboration and supply agreement for a clinical trial. This trial is CytomX's first-in-human Phase 1 study, evaluating the clinical efficacy of CX-801. CX-801 is a dually-masked interferon alpha2b cytokine, being tested in conjunction with Merck's renowned anti-PD-1 therapy, KEYTRUDA (pembrolizumab). Interferon alpha-2 b is a potent cytokine recognized for its clinical efficacy against various cancer types. Thus, such developments for interferons in the region are expected to boost the growth of the market during the forecast period.
Thus, the high burden of hepatitis, renal cell carcinoma, and strategic activities by the market players are expected to boost the market in North America during the forecast period.
Interferons Industry Overview
The interferons market is semi-consolidated and consists of local and global players. The market players are engaged in research and development and strategic activities such as product launches and mergers and acquisitions to gain the majority share in the market. Some companies dominating the market are Merck & Co. Inc., Biogen Inc., Bayer AG, Amega Biotech, and F. Hoffmann-La Roche Ltd.
Interferons Market Leaders
-
Merck & Co.,Inc.
-
Biogen Inc
-
Bayer AG
-
Amega Biotech
-
F. Hoffmann-La Roche Ltd
*Disclaimer: Major Players sorted in no particular order
Interferons Market News
- August 2024: Pharmaand GmbH (pharma&) announced that the European Commission (EC) granted marketing authorization for a Type II variation of Pegasys (peginterferon alfa-2a). This authorization allows Pegasys to be used as a monotherapy treatment for adults diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET).
- September 2023: Eiger Biopharmaceuticals Inc. provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. This update was based on the most recent communications with the US Food and Drug Administration.
Interferons Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence Of Diseases Such As Hepatitis, Multiple Sclerosis, And Cancers
- 4.2.2 High Target Affinity And Specificity Of Interferons
-
4.3 Market Restraints
- 4.3.1 High Research and Development Costs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Service
- 5.1.1 Inteferon Alpha
- 5.1.2 Inteferon Beta
- 5.1.3 Inteferon Gamma
-
5.2 By Application
- 5.2.1 Hepatitis B
- 5.2.2 Hepatitis C
- 5.2.3 Melanoma
- 5.2.4 Leukemia
- 5.2.5 Multiple Sclerosis
- 5.2.6 Renal Cell Carcinoma
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Amega Biotech
- 6.1.2 Bayer AG
- 6.1.3 Biogen Inc.
- 6.1.4 Biosidus
- 6.1.5 Merck & Co. Inc.
- 6.1.6 Novartis AG
- 6.1.7 Pfizer Inc
- 6.1.8 F. Hoffmann-La Roche Ltd
- 6.1.9 Zydus Cadila
- 6.1.10 AOP Orphan Pharmaceuticals AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityInterferons Industry Segmentation
As per the scope of the report, interferons are a class of proteins generated and released by the host cells against the presence of pathogenic microbes like bacteria, viruses, fungi, and tumor cells. Interferon proteins belong to a class of glycoproteins, namely cytokines, and are generally considered the first line of defense against microbial infections.
The interferons market is segmented by product type, application, and geography. By product type, the market is segmented as interferon alpha, interferon beta, and interferon gamma. By application, the market is segmented as hepatitis B, hepatitis C, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers market size and forecasts for the interferons market in value (USD) for the above segments.
| By Service | Inteferon Alpha | |
| Inteferon Beta | ||
| Inteferon Gamma | ||
| By Application | Hepatitis B | |
| Hepatitis C | ||
| Melanoma | ||
| Leukemia | ||
| Multiple Sclerosis | ||
| Renal Cell Carcinoma | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Interferons Market Research FAQs
How big is the Interferons Market?
The Interferons Market size is expected to reach USD 10.15 billion in 2024 and grow at a CAGR of 3.91% to reach USD 12.30 billion by 2029.
What is the current Interferons Market size?
In 2024, the Interferons Market size is expected to reach USD 10.15 billion.
Who are the key players in Interferons Market?
Merck & Co.,Inc., Biogen Inc, Bayer AG, Amega Biotech and F. Hoffmann-La Roche Ltd are the major companies operating in the Interferons Market.
Which is the fastest growing region in Interferons Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Interferons Market?
In 2024, the North America accounts for the largest market share in Interferons Market.
What years does this Interferons Market cover, and what was the market size in 2023?
In 2023, the Interferons Market size was estimated at USD 9.75 billion. The report covers the Interferons Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Interferons Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Interferons Industry Report
The Global Interferon Market is segmented by product type, application, and geography. The market segmentation includes interferon alpha, beta, and gamma, as well as applications such as hepatitis B, hepatitis C, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma. The geographical segmentation covers North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
The market overview reveals significant insights into industry trends and market growth. The industry analysis highlights the market forecast and market outlook, providing an in-depth understanding of the market value and market size. The industry reports and market report offer comprehensive market data, including market segmentation and market review.
The market leaders play a crucial role in shaping the market predictions and market trends. The industry research and industry information provide valuable industry statistics and industry size, enhancing the understanding of market dynamics. The industry sales and market growth rate are essential factors in evaluating the market's performance.
The report example and report pdf offer a detailed industry overview, with industry outlook and industry research being key components. The industry trends and market forecast are essential for understanding future market developments. The market analysis and market value provide insights into the economic aspects of the market.
The market segmentation and market review offer a thorough analysis of the market, while the market outlook and market predictions provide a forward-looking perspective. The industry statistics and industry size are crucial for understanding the market's scale and scope. The research companies contribute to the industry research, providing valuable data and insights.
Overall, the Global Interferon Market report is a comprehensive source of industry information, offering a detailed market overview and industry analysis. The market report and industry reports provide valuable insights into market trends, market growth, and market leaders, making it an essential resource for understanding the interferon market.
